No studies have examined the effect of mineralocorticoid receptor antagonist therapy on new-onset diabetes. In addition, though the combination of diabetes and chronic heart failure (CHF) carries a poor prognosis, few studies have examined predictors of new-onset diabetes in those with CHF.
Introduction
Patients with heart failure are at increased risk of developing newonset diabetes mellitus, and co-existent diabetes is associated with worse heart failure symptoms, higher rates of hospitalization, and reduced survival. 1 Why the risk of incident diabetes is increased in heart failure is uncertain, and relatively little is known about the variables predicting this risk. To date, only the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) and Carvedilol Or Metoprolol European Trial (COMET) trials have examined this question. 2, 3 It is known, however, that angiotensin II receptor blockers (ARBs), and possibly angiotensin-converting enzyme (ACE) inhibitors, reduce the risk of developing diabetes in patients with heart failure (and also in those with hypertension and impaired glucose tolerance). 4 -6 It is therefore of interest to know whether the other type of renin-angiotensin -aldosterone blockers used in heart failure, mineralocorticoid receptor (MR) antagonists, affect the risk of incident diabetes. Data on the effect of MR antagonists on glycaemic indices are conflicting. Treatment with the non-selective MR antagonist, spironolactone, has consistently been associated with elevations in haemoglobin A1c (HbA 1c ) in patients with and without diabetes, 7 -10 suggesting that spironolactone may increase the risk of new-onset diabetes. In contrast, spironolactone has been shown to improve insulin sensitivity in patients with non-alcoholic fatty liver disease (NAFLD), a condition closely associated with insulin resistance. 11 Even less is known about the actions of the more selective MR antagonist eplerenone. However, in one trial comparing the effects of spironolactone and eplerenone in patients with chronic heart failure, spironolactone recipients showed increases in both HbA 1c and cortisol levels, plus a fall in adiponectin, whereas no changes occurred in eplerenone recipients. 7 New-onset diabetes was a pre-defined secondary endpoint in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). In this report we describe the effect of eplerenone, compared with placebo, on new-onset diabetes and the baseline predictors of incident diabetes.
Methods
The primary aim of EMPHASIS-HF was to investigate the effect of eplerenone, added to evidence-based therapy, on clinical outcomes in patients with systolic heart failure and mild symptoms [patients had to be in New York Heart Association (NYHA) functional class II]. The design, protocol, and results of the trial are available elsewhere. 12, 13 Briefly, 2737 patients with mild symptoms and a left ventricular ejection fraction ≤ 0.35 were randomized to receive either the aldosterone antagonist, eplerenone (up to 50 mg daily), or placebo in addition to recommended therapy (including an ACE inhibitor or ARB and beta-blocker). Patients were followed up for a median of 21 months to assess the effect on a composite outcome of cardiovascular death or hospitalization for heart failure. Patients were seen 4 weeks after randomization and then every 4 months during trial follow-up. All patients provided written informed consent and the protocol was approved by the ethics committee at each participating institution. The trial was supported by the study sponsor, Pfizer.
Analysis population
The analysis population included all EMPHASIS-HF participants in the full analysis set but excluding those known to have diabetes at baseline.
Diabetes status at baseline was determined from the following parts of the study case report form: (i) significant medical condition report at screening; (ii) the aetiology of heart failure report and prior index hospitalization at screening; (iii) the medical history page; and (iv) use of medications for diabetes in the 3 months prior to screening or at the randomization visit.
Diagnosis of new-onset diabetes
Incident diabetes was a pre-specified secondary endpoint in EMPHASIS-HF. Investigators were asked to check for (and report) the occurrence of a new diagnosis of diabetes at each postrandomization trial visit. Details of the diagnosis of diabetes [date of diagnosis, details of the criteria for diagnosis [elevated fasting plasma glucose ( ≥ 7.0 mmol/L), random glucose ( ≥ 11.1 mmol/L), or oral glucose tolerance test (fasting plasma glucose ≥ 7.0 mmol/L and/or 2 h plasma glucose ≥ 11.1 mmol/L)], hypoglycaemic medication prescribed, and lifestyle modifications prescribed were documented on a specific incident diabetes case report form. Fasting blood samples were not collected in EMPHASIS-HF and formal tests for diabetes were not performed.
Statistical methods
To assess the effect of eplerenone on new-onset diabetes in patients without diabetes at baseline, the numbers of subjects developing diabetes in each treatment arm were compared in a univariate Cox proportional hazard analysis, with treatment allocation (eplerenone or placebo) as the only factor in the model. Cumulative event rates for new-onset diabetes were compared using the log rank test. In an attempt to exclude any potential effect of competing risk introduced by an effect of eplerenone on mortality, an additional composite endpoint of all-cause mortality or new-onset diabetes was analysed.
To identify independent predictors of new-onset diabetes, data from both treatment arms were pooled. Numerous commonly recorded demographic, clinical, laboratory, and medication variables at baseline were considered as predictors of diabetes (see Table 1 ). Patients who did and did not develop diabetes during the trial were compared with respect to these baseline variables using two-sample t-tests (for continuous variables) and Fisher's exact tests (for categorical variables). Univariate Cox proportional hazard analyses were employed to assess the strength of association between each of these baseline variables and new-onset diabetes. In subsequent multivariate Cox proportional hazard analyses to identify independent predictors, two approaches were used. In the first approach, a full multivariate Cox proportional hazard model (Model 1) was built by including all variables associated with new-onset diabetes (P , 0.10 identified from univariate Cox proportional hazard analyses) but for highly correlated variables [e.g. body mass index (BMI), waist circumference, and weight] only the variable that provided the most information was included. In the second approach, a reduced multivariate model (Model 2) was established from the full multivariate Cox proportional hazard model (Model 1) using a stepwise selection process to identify relevant variables. For the univariate and multivariate analyses, hazard ratios (HRs) for new-onset diabetes are provided per one standard deviation of each continuous variable to facilitate comparison. Finally, receiver operating characteristic (ROC) curve analysis was performed to calculate the c-statistics for both Models 1 and 2.
All P-values were two sided, and P , 0.05 was considered statistically significant. Analyses were performed using Statistical Analysis Software (SAS, Window Version V8).
Results
Of the 2737 patients randomized in EMPHASIS-HF, 891 (32.5%) were known to have diabetes at baseline. Analyses in this report are limited to the 1846 patients without known diabetes at baseline. diabetes at baseline were diagnosed with diabetes, an approximate incidence of 21 cases per 1000 patient-years.
Effect of eplerenone on new-onset diabetes
The baseline characteristics of patients without diabetes at baseline were balanced between randomized treatment arms (Supplementary material online, Table S1 ). Eplerenone had no effect on the incidence of new-onset diabetes; 33 (3.7%) of 894 patients assigned to treatment with eplerenone developed diabetes compared with 36 (3.8%) of 952 patients assigned placebo ( Figure 1 ). This corresponded to a HR of 0.94 [95% confidence interval (CI) 0.59 -1.52, P ¼ 0.81]. The eplerenone:placebo HR for the composite of all-cause mortality or new-onset diabetes was 0.80 (95% CI 0.64 -1.01); P ¼ 0.06 ( Figure 2 ).
Predictors of new-onset diabetes in mild heart failure
The baseline characteristics of patients who did and did not develop new diabetes are shown in Table 1 . In univariate Cox proportional hazard analysis, the strongest predictors of new-onset diabetes (in decreasing order of magnitude as estimated by the Wald x 2 statistic) were: higher serum alanine aminotransferase (ALT), use of digitalis, higher serum aspartate aminotransferase (AST), higher waist circumference, higher weight, higher BMI, longer duration of heart failure, current or previous smoking, higher heart rate, hypertension, higher systolic blood pressure, lower age, higher diastolic blood pressure, higher serum potassium, not using a beta-blocker. and the presence of atrial fibrillation (see Table 2 ). In multivariable Cox proportional hazard analysis, Model 1 [full model where only variables with P , 0.10 in univariate analysis were included but for the following groups of highly correlated variables only the variable that provided the most information was included: (i) systolic and diastolic blood pressure: systolic blood pressure selected; (ii) weight, waist circumference, and BMI: waist circumference selected; (iii) ALT and AST: ALT selected], only seven variables remained significantly associated with new-onset diabetes (see Table 3 ). These independent predictors of new-onset diabetes (in decreasing order of magnitude as estimated by the Wald x 2 statistic) were: use of digitalis, higher serum ALT, longer heart failure duration, current or previous smoking, higher waist circumference, lower age, and higher systolic blood pressure. Variables identified in Model 2 (the reduced model) were similar.
In the ROC curve analysis, the individual c-statistic for variables independently associated with new-onset diabetes varied from 0.53 to 0.65 in Models 1 and 2. When all the relevant variables were combined, the overall c-statistic was 0.74 for Model 1 and 0.76 for Model 2 (see Table 4 ).
Discussion
That diabetes is common in patients with heart failure 1 was confirmed in the present study. Thirty-two per cent of participants had diabetes at baseline, and in those without diabetes at baseline the incidence of new diabetes was 21 cases per 1000 patient-years of follow-up. This incidence is similar to that reported in two other clinical trials in chronic heart failure 2,3 and is considerably higher than expected in the general population, e.g. the incidence of physician-diagnosed diabetes was 12.8 cases per 1000 patient-years in American adults aged 65 -79 years in 2009. 14 The effect of MR antagonists on the risk of diabetes is difficult to predict. Primary hyperaldosteronism is a state of insulin resistance, and aldosterone levels are associated with insulin resistance in normotensive and hypertensive patients. 15 In an observational study of patients with primary hyperaldosteronism, treatment with either spironolactone or adrenalectomy returned insulin sensitivity parameters towards normal. 16 In another study, the combination of vitamin E and spironolactone for 8 weeks decreased insulin levels and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) compared with vitamin E alone in patients with biopsy-proven NAFLD, 11 while spironolactone therapy has shown benefical cardiac effects in patients with metabolic syndrome. 17 Low serum potassium is also known to be associated with increased risk of new-onset diabetes in both normotensive and treated hypertensive patients, and MR antagonists increase potassium. 18, 19 On the other hand, spironolactone therapy has consistently led to modest increases in HbA 1c in clinical trials of patients with type 2 diabetes alone or complicated by nephropathy or poorly controlled hypertension. 8 -10 In a further study of 107 patients with mild chronic heart failure, spironolactone therapy increased HbA 1c and cortisol levels and reduced adiponectin levels over 4 months, 7 findings which might be expected to herald an increased risk of developing diabetes. In contrast, in The x 2 statistic, hazard ratio, 95% CI, and P-values are based on multivariate Cox proportional hazard analysis including all predictor variables with P , 0.10 in univariate analysis. For the following highly correlated variables, the following variables were selected by a stepwise process:
†Systolic and diastolic blood pressure: systolic blood pressure included. †Weight, waist circumference. and BMI: waist circumference selected. †ALT and AST: ALT selected. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; SBP, systolic blood pressure.
that study eplerenone had no such effects, suggesting the possibility of a differential effect, depending on the selectivity of MR blockade. Consistent with this, we found no effect of eplerenone on incident diabetes in the present study, although the number of affected patients was relatively small. We identified seven factors independently associated with newonset diabetes. Of these, longer duration of heart failure, higher serum ALT, and higher waist circumference were expected predictors. Serum ALT has been associated with incident diabetes in a number of studies in several different populations, including heart failure. 2, 20, 21 Usually this is thought to be because ALT is considered a surrogate marker for NAFLD, a condition characterized by insulin resistance and therefore a powerful risk factor for diabetes. Whether or not this is the explanation in heart failure is less certain because transaminases may be elevated due to liver congestion or ischaemia. Interestingly, waist circumference performed slightly better as a predictor compared with either BMI or body weight. Digitalis was strongly predictive of new-onset diabetes, a finding noted in earlier studies but unexplained. 2, 3 One possibility is that digitalis use is a marker of heart failure severity, and there is some evidence that the risk of diabetes increases with increasing severity of heart failure. 22 However, it has also been suggested that reduced activity of Na/K-ATPase may play a role in the pathogenesis of diabetes mellitus, and digoxin is an inhibitor of this enzyme. 23, 24 Lower age was also associated with higher risk of developing diabetes. Though at first sight surprising, this was noted in previous studies 2, 3 and seems likely to reflect either the different phenotypes of older and younger trial participants [data exist to support this: in a substudy of 2107 patients in CHARM, the prevalence of obesity (BMI ≥ 30 kg/m 2 ) was four times higher in patients with chronic heart failure aged ,50 years than in patients aged ≥ 80 years] or the longer survival of younger participants recruited in trials of chronic heart failure patients. When the independent variables were combined in predictive models, they provided reasonable c-statistics of 0.74-0.76. Indeed, this is comparable with models for prediction of diabetes in the general population, despite not containing any direct glucose-related measures. 25 Various strengths and weaknesses of the data contained in this report warrant discussion. This is the first randomized trial to report the effect of MR antagonist therapy on new-onset diabetes, and participants were well phenotyped at baseline. While diabetes was physician-diagnosed and not based on trial-required measurements of fasting plasma glucose, participants were specifically asked about new-onset diabetes at each trial visit. Data for family history of diabetes were not available. The numbers of participants that developed diabetes was relatively small, so statistical power to detect a modest effect of eplerenone on new-onset diabetes was limited.
In summary, information available from commonly measured clinical and laboratory variables predicts the development of newonset diabetes in patients with symptomatically mild systolic heart failure with similar accuracy to models used in other populations. Treatment of these patients with eplerenone had no effect on the development of diabetes compared with placebo.
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